Antibody-drug conjugates (ADCs) are therapies that target cancer cells with antigen-specific antibodies and highly toxic payloads. ADCs are currently generating interest among drug developers, contract manufacturing companies, regulatory agencies, and other stakeholders.
• How is the development of technologies contributing to the expansion of applications for ADCs beyond oncologic indications?
• What are the key technology platforms, patents, analytical techniques, and manufacturing developments driving advancements in ADC development?
• What key growth opportunities are emerging in the field of ADCs, and how can stakeholders and key players leverage them?
Sign up for a complimentary Growth Pipeline Dialog™
A Growth Pipeline Dialog is a structured open discussion with our growth experts providing unparalleled industry intelligence, technology advancements, and proven implementation best practices. This discussion will spark innovative thinking and help generate a pipeline of growth opportunities you can leverage to maximize your company’s future growth potential.